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REVIEW ARTICLE

The Translational Biology of Remyelination:
Past, Present, and Future
Robin J. M. Franklin1 and Vittorio Gallo2
Amongst neurological diseases, multiple sclerosis (MS) presents an attractive target for regenerative medicine. This is because
the primary pathology, the loss of myelin-forming oligodendrocytes, can be followed by a spontaneous and efficient regenerative process called remyelination. While cell transplantation approaches have been explored as a means of replacing lost oligodendrocytes, more recently therapeutic approaches that target the endogenous regenerative process have been favored.
This is in large part due to our increasing understanding of (1) the cell types within the adult brain that are able to generate
new oligodendrocytes, (2) the mechanisms and pathways by which this achieved, and (3) an emerging awareness of the reasons why remyelination efficiency eventually fails. Here we review some of these advances and also highlight areas where
questions remain to be answered in both the biology and translational potential of this important regenerative process.
GLIA 2014;62:1905–1915
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Introduction

D

emyelination, the loss of myelin from an otherwise intact
axon, is an unusual pathological event in the CNS is that
it often followed by remyelination, a spontaneous regenerative
process involving the generation of new oligodendrocytes and
the formation of new myelin sheaths (Franklin and ffrenchConstant, 2008; Gallo and Armstrong, 2008). With the restoration of myelin comes the return of myelin functions lost
during demyelination, namely, salutatory conduction, the
maintenance of axonal integrity and the recovery from functional deficits (Duncan et al., 2009; Franklin et al., 2012).
Primary demyelination is a feature of several neurological
conditions. In those where demyelination features as a single
acute event, such as in traumatic injury, the likelihood is that
these lesions will, eventually, undergo spontaneous repair
(e.g., Lasiene et al., 2008). However, the situation is somewhat different in the most prevalent demyelinating disease of
the adult central nervous system (CNS), multiple sclerosis
(MS). MS is a chronic demyelinating disease, often of many
decades duration, in which autoimmune-mediated damage to
myelin (and in the acute inflammatory phase, to axons) continues to occur episodically. Like all regenerative processes,

the efficiency of remyelination declines progressively throughout adulthood (Goldschmidt et al., 2009): the basis of this
decline is discussed later in this review. The effects of aging
on remyelination are likely to have a profound bearing on the
natural history of the disease even though the rate at which
remyelination occurs in humans is difficult to assess. The
observation that extensive remyelination can be found in
older individuals with MS (Patrikios et al., 2006) can not be
taken as evidence that remeylination is unaffected by aging
(which would make remyelination unique amongst regenerative processes), since in this study there was no way of knowing when a particular lesion occurred or how long it took to
remyelinate. The consequence of failing remyelination is that
axons remain chronically demyelinated and vulnerable to the
irreversible degeneration that underpins the currently untreatable secondary progressive phase of MS. By implication,
reversing the declining efficiency of remyelination by its therapeutic enhancement is likely to prove an effective means of
addressing the unmet clinical need of providing neuroprotection in the secondary progressive MS (Franklin et al., 2012).
Although remyelination enhancement could theoretically be
achieved by transplantation of myelinogenic cells (despite the
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many practical hurdles of cell identity and source, delivery,
and histocompatability), current evidence suggest that this
will not be necessary since the proof-of-principle studies in
mice indicate that the effects of ageing on the spontaneous
regenerative process are reversible and that strategies targeting
the endogenous remyelination will prove effective throughout
the disease duration (Huang et al., 2011; Ruckh et al., 2012).
While cell transplantation remains (and is likely to remain)
the approach of choice for the demyelinating conditions of
genetic origin (Goldman et al., 2012; Gupta et al., 2012),
where the oligodendrocyte lineage is inherently defective, promotion of endogenous remyelination is the current favored
strategy for remyelination in MS and will therefore form the
focus of this review.
Endogenous Adult Progenitor Cells with the
Potential to Remyelinate
Substantial OL death occurs in MS and demyelinating disorders (Barnett and Prineas, 2004; Cannella et al., 2007), and
in all animal models of demyelination (Aguirre et al., 2007;
Mason et al., 2004; Mi et al., 2011; Woodruff and Franklin,
1999; Zhou et al., 2012). Induction of apoptosis in OLs by
lentivirus-mediated caspase 9 expression under the MBP promoter results in rapid focal demyelination (Caprariello et al.,
2012), demonstrating that demyelination is initiated by OL
death itself. Oligodendrocytes (OLs) and Schwann cells are
the only cells in the central nervous system that are able to
repair demyelinated axons. Schwann cell remyelination of the
CNS, which has been reported in MS, spinal cord injury and
various experimental models (Itoyama et al., 1983; Zawadzka
et al., 2011), occurs under particular circumstances such as
when demyelination is associated with astrocyte loss. Here,
we will focus on oligodendrocyte remyelination. Although
cellular interactions between OLs and other cell types of the
CNS regulate the complex process of remyelination, OLs
themselves are ultimately responsible for myelin repair. Therefore, recognizing and understanding the intrinsic OL potential to remyelinate under different pathological conditions,
and the cellular and molecular signals that regulate this process are crucially important to design future therapies aimed
at promoting remyelination.
It is well established that remyelination primarily occurs
from endogenous neural progenitor cells (NPCs) and OPCs
surviving demyelinating insults and generating new, mature
OLs. Analysis of the spatio-temporal dynamics of cellular
recovery in demyelinated lesions demonstrated that cells with
an OPC phenotype first appear before new myelinating oligodendrocytes are generated (Aguirre et al., 2007; Fancy et al.,
2004; Levine and Reynolds, 1999; Watanabe et al., 2002).
Genetic fate-mapping studies using a variety of reporter
proteins expressed under the control of OPC gene promoters
1906

directly demonstrated enhanced oligodendrogenesis from
OPCs after demyelination (Aguirre et al., 2007; Zawadzka
et al., 2010; Guo et al., 2011; Nakatani et al., 2013). Importantly, this pool of OPCs is renewable between demyelinating
episodes (Penderis et al., 2003). A more recent study used a
retroviral reporter system to selectively, genetically and permanently label endogenous dividing NG2-expressing progenitors
after spinal cord injury confirmed that this cell population is
actively involved in myelin repair (Powers et al., 2013). These
findings are consistent with reports demonstrating that grafted
rodent and human glial progenitors, as well as iPSC-derived
OPCs, can extensively repopulate and remyelinate demyelinated areas (Groves et al., 1993; Najim et al., 2013; Windrem et al., 2004). These findings indicate that endogenous
adult OPCs and NPCs represent the major cellular targets to
promote remyelination in the CNS.
A therapeutic approach of exploiting endogenous progenitor cells for remyelination therefore calls for clearer
understanding of many intrinsic properties of adult OPCs,
namely: (1) What are the characteristic features of activated,
remyelinating OPCs? (2) What is their potential to migrate
to different brain regions to repopulate demyelinated areas
(3) How efficient are these progenitor populations in expanding to regenerate the necessary OL numbers, and how effectively do they differentiate into mature, myelinating OLs? (4)
Which and where are the major NPC/OPC populations capable of regenerating oligodendrocytes and myelin after demyelination? (5) Are there injury-induced OPCs derived from
other cell lineages? These issues have been studied for many
years, and some significant progress has recently been made
to further uncover the molecular and developmental properties of these progenitors, and identify specific cellular phenotypes and their regenerative potential.
The endogenous population of adult OPCs is characterized by expression of the PDGFRa (Kang et al., 2010; Zhu
et al., 2008). NG2 is highly responsive to injury (e.g., Rhodes
et al., 2006), and recently its role during remyelination was
demonstrated, not only in OPC proliferation, but also as a
component of demyelination-induced inflammatory damage
(Kucharova et al., 2011). Fate mapping studies and use of
different transgenic mouse strains demonstrated that these
cells are capable of efficiently regenerating myelinating OLs
after demyelination (Aguirre et al., 2007; Zawadzka et al.,
2010). Like perinatal OPCs, adult OPCs express the transcription factors Olig1/2 (Aguirre et al., 2007; CassianiIngoni et al., 2006; Fancy et al., 2004; Ligon et al., 2006; Lu
et al., 2002; Sim et al., 2002; Zhou et al., 2001), Ascl1
(Nakatani et al., 2013; Parras et al., 2004) and Nkx2.2
(Fancy et al., 2004; Soula et al., 2001; Zhou et al., 2001)
under physiological and pathological conditions. Importantly,
Volume 62, No. 11
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FIGURE 1: Phenotype of endogenous adult progenitor cells with
the potential to remyelinate. The figure shows cellular proteins
that are transiently upregulated (large arrow on the left) in
endogenous adult OPCs after demyelination and can be used to
identify “activated OPCs”, i.e. cells that respond to the demyelination insult. These proteins include cell proliferation markers,
membrane and signaling proteins, and transcription factors.

expression of the marker proteins that characterize OPCs in
the normal and pathological rodent brain has also been
revealed in MS tissue (Arnett et al., 2004; Chang et al.,
2002; Nait-Oumesmar et al., 2007). The identification and
characterization of OPCs in the pathological brain raises the
important question of whether there is indeed a phenotype
corresponding to an “activated” OPC (Fig. 1).
Both BrdU pulse-chase and fate mapping studies demonstrated that dividing OPCs expressing proliferation markers
are actively involved in remyelination (Aguirre et al., 2007;
Carroll et al., 1998; Gensert et al., 1997). Intrinsic regulators
of OPC proliferation also play an important role in remyelination. In response to CNS demyelination, loss of Cdk2
alters OPC renewal, cell cycle exit, and differentiation (Caillava et al., 2011). Furthermore, Cdk2 deletion accelerates
remyelination of demyelinated CNS axons from parenchymal
OPCs (Caillava et al., 2011). Interestingly, Cdk4, not Cdk2,
may play a crucial role in PNS remyelination after nerve
injury (Atanasoski et al., 2008), indicating that different
molecular mechanisms regulate OPC and Schwann cell precursor expansion and recruitment during CNS versus PNS
remyelination. Finally, developmental regulation of cell cycle
activity (Belachew et al., 2002), together with impaired
recruitment and differentiation (Shen et al., 2008; Sim et al.,
November 2014

2002), likely underlies the reduction in the OPC regenerative
potential observed in adult compared with the developing
brain (Sim et al., 2002).
Other cellular features, besides proliferation markers,
appear to be typical of “activated” OPCs. Fibroblast growth
factor receptor 1 (FGFR1) expression is upregulated in OPCs
after cuprizone-induced demyelination and its deletion during
chronic demyelination reduces the number of OPCs, but promotes their differentiation to oligodendrocytes (Zhou et al.,
2012). Both Shh and a member of the SoxF transcription factor family, Sox 17, are expressed at high levels in OPCs after
demyelination, but are either undetectable or expressed at
much lower levels in OPCs under normal physiological conditions (Ferent et al., 2013; Ming et al., 2013; Moll et al.,
2013). Shh and Sox17 have both been identified as positive
regulators of oligodendrogenesis and remyelination (Ferent
et al., 2013; Ming et al., 2013), and Shh transcripts are
detected only in OPCs engaged in remyelination (Ferent
et al., 2013). Musashi1 (Msi1), Myt1, Tcf4 (Tcf7l2) and
Nkx2.2 are expressed in OPCs in white matter regions during
development, and their expression is upregulated in OPCs
after demyelination (Dobson et al., 2008; Fancy et al., 2004,
2009; Sim et al., 2002; Vana et al., 2007; Watanabe et al.,
2004). Furthermore, although Olig2-expressing progenitors
appear to be a major cell population involved in remyelination (Aguirre et al., 2007; Fancy et al., 2004; Menn et al.,
2006), maintenance of nuclear Olig2 expression is required
for oligodendrocyte regeneration, as translocation of Olig2
from the nucleus to the cytoplasm is associated with induction of GFAP expression and astrogliogenesis (Cassiani-Ingoni
et al., 2006). Finally, Olig1, which relocates to the nucleus in
“activated” OPCs, and Ascl1/Mash1 are also required for
remyelination (Arnett et al., 2004; Nakatani et al., 2013). Loss
of Olig1 in transplanted NPCs results in astrocyte generation,
rather than oligodendrocytes (Whitman et al., 2012), and selective deletion of Ascl1/Mash1 in OPCs prevents remyelination
(Nakatani et al., 2013). In conclusion, it appears that expression of proliferation markers, as well as high levels of FGFR1,
Shh, Sox17, Msi1, Myt1, Nkx2.2, Tcf4, and Ascl1/Mash1,
together with nuclear Olig1/2 expression, may characterize
“activated” OPCs engaged in the remyelination process.
Aging strongly affects the potential of endogenous
OPCs to remyelinate (Hampton et al., 2012; Ruckh et al.,
2012; Sim et al., 2002) and epigenetic mechanisms modulating OPC differentiation program are also regulated by age
(Shen et al., 2008). Histone deacetylases (HDACs) are
involved in downregulation of inhibitors of oligodendrocyte
differentiation during development (Marin-Husstege et al.,
2002; Ye et al., 2009). The efficiency of this process is
affected by aging, and remyelination is impaired by in vivo
administration of HDAC inhibitors acting on OPCs (Shen
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et al., 2008). Therefore, it appears that HDACs play an
important role in remyelination efficiency and their activity is
required to suppress inhibitors of OPC differentiation. In
addition to HDACs, Na1-dependent deacetylases also play a
role in oligodendrocyte regeneration and remyelination efficiency. A recent study demonstrated that the nuclear sirtuin
SIRT1 acts as an inhibitor of remyelination, because inactivation of this protein leads to expansion of the OPC pool,
enhanced remyelination and delayed paralysis in animal models of demyelination (Rafalski et al., 2013). In summary, epigenetic reactivation of developmental mechanisms in OPCs is
likely to be an essential component of oligodendrogenesis and
remyelination. It will have to be established whether activation of epigenetic mechanisms in distinct pools of OPCs
determines recruitment of subpopulations of these cells during myelin regeneration processes of the adult brain.
Two major sources of OPCs are present in the adult
brain: the subventricular zone (SVZ) and the parenchyma,
which includes the white matter itself (Aguirre et al., 2004,
2007; Levison and Goldman, 1993; Menn et al., 2006; NaitOumesmar et al., 1999). The SVZ progenitors involved in
remyelination of white matter regions express NG2 and
Olig2, as well as markers of Type-C cells, including EGFR
(Aguirre et al., 2004, 2007; Menn et al., 2006; NaitOumesmar et al., 1999). Differently from Type-B cells, SVZ
OPCs actively divide and their proliferation rate is enhanced
after demyelination of the corpus callosum (Aguirre et al.,
2007; Menn et al., 2006; Nait-Oumesmar et al., 1999). Both
parenchymal and SVZ progenitor pools participate in remyelination, although their relative contributions to oligodendrocyte regeneration and remyelination of demyelinated lesions
has not yet been quantitatively determined. Furthermore,
although many of the molecular pathways involved in proliferation, migration and differentiation of SVZ and parenchymal OPCs after demyelination have been identified, it is still
unclear whether these distinct pools of endogenous progenitors are functionally distinct and whether intrinsic molecular
mechanisms distinguish their proliferative responses to demyelination. Future studies should be aimed at revealing these
differences, by, for example, selectively inhibiting recruitment
of either SVZ or parenchymal OPCs in order to measure
their relative involvement in remyelination.
A question of great interest in oligodendrocyte regeneration and remyelination is whether specific neural cell lineages
display plasticity in postnatal and adult brain under pathological conditions, i.e., can neuronal or glial progenitors
“committed to” either a neuronal or an astrocytic fate become
diverted to generate different progenies? The potential for
instructing immature neurons to generate glia would enable
larger pools of endogenous neural progenitors to be targeted
and avoid some of the problems associated with heterologous
1908

transplantation as a therapeutic approach, such as rejection of
heterologous cells, and efficiency and invasiveness of the grafting process. Studies have described changes in cell fate potential after genetic manipulation of specific neuronal progenitor
cell populations under normal physiological conditions and in
culture. For example, adult hippocampal NPCs change their
fate from neurons to OPCs and oligodendrocytes after
retroviral-mediated overexpression of bHLH transcription factor Ascl1 (Mash1) (Jessberger et al., 2008). This process is
regulated by cell-autonomous and niche-dependent mechanisms (Jessberger and Gage, 2009). Cell lineage plasticity also
occurs in GAD65- and Dcx-expressing neuroblasts of the
adult SVZ, which generate oligodendrocytes in corpus callosum after focal demyelination (Jablonska et al., 2010). This
process occurs together with induced expression of Mash1
and Olig2 in these progenitors, strongly suggesting that
bHLH transcription factors act coordinately as essential regulators of oligodendrogenesis from GAD65- and Dcxexpressing neuroblasts. The BMP antagonist chordin was
identified as a SVZ signal that promotes oligodendrogenesis
from these progenitors, indicating that niche-dependent
mechanisms also regulate lineage plasticity of neuroblasts in
the SVZ (Jablonska et al., 2010).
One can propose that cell fate plasticity is a major factor supporting endogenous brain repair. Glial progenitor cell
lineage plasticity is not entirely surprising, since hippocampal
and SVZ astroglial stem cells display multipotency both in
vitro and after grafting in vivo (Doetsch et al., 1999; Eriksson
et al., 2003; Ganat et al., 2006; Laywell et al., 2000; Yaganisawa et al., 2005), however the host environment is critical in
determining their survival and differentiation. Various growth
factors, neurotrophins, cytokines, and proinflammatory molecules are present in the cellular environment of a demyelinated lesion, where it is likely that they promote or restrict
cell fate plasticity in activated neuronal or glial progenitors
during regeneration. Therefore, a major aim of future studies
will be defining endogenous signaling pathways activated
under pathological conditions, and demonstrating their effects
on neural progenitor cell plasticity.
The experimental literature discussed above points to a
major role of endogenous NG2/PDGFRa-expressing progenitors in remyelination. These cells represent an important target to promote myelin repair, as they have the potential to
generate both oligodendrocytes and Schwann cells under
pathological conditions (Zawadzka et al., 2010). However,
there are still major issues that will have to be resolved and
that directly affect the outcome of endogenous OPCmediated remyelination. It is still undefined to what extent
OPC/NPC death occurs in MS lesions (Cui et al., 2013),
with subsequent reduction of the endogenous pools of these
cells. This is an important and unresolved question, as the
Volume 62, No. 11
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size of this pool directly impacts the efficiency of the repair
process (see Franklin and ffrench-Constant, 2008 for review).
Furthermore, the influence of the pathological cellular environment, in particular inflammation, can influence the
response of NG2 cells to demyelination (Rhodes et al.,
2006). These factors will have to be carefully taken into
account in designing future strategies aimed at promoting
OPC-mediated
oligodendrocyte
regeneration
and
remyelination.
Functional Role of Neurons in Remyelination
Death of oligodendrocytes and loss of myelin represents a
major component of the degenerative processes associated
with myelin pathology and demyelination. However, it has
become clear that neuronal loss and axonal damage and
degeneration also play a crucial role in myelin diseases,
including MS (Ganter et al., 1999; Trapp et al., 1998). Evidence obtained in animal models of demyelination, as well as
in human MS tissue, supports the idea that compromised
axonal function and neuronal loss both cause long-term
impairment observed in the chronic progressive phase of MS
(Dubois-Dalcq et al., 2005). Therefore, MS and other demyelinating diseases are now regarded as a combination of inflammatory damage to oligodendrocytes and neurodegeneration.
Similar to the process that occurs during development,
repair of a demyelinated lesion depends on appropriate
matching between oligodendrocytes and axons, i.e. on a coordinated regenerative process that involves both glia and neurons. The number of oligodendrocytes necessary to repair a
lesion will ultimately depend on the size of the lesion, in particular the number of demyelinated axons and the length of
demyelinated segments. However, the cellular and molecular
mechanisms that regulate appropriate myelin thickness and
intermodal length during remyelination are still unknown.
Are the same axonal signals that act on oligodendrocytes to
modulate developmental myelination also effective during
remyelination, and what types of communication occur
between axons and oligodendrocytes during this process?
Some of these crucial cellular interactions have been identified, including electrical activity-mediated communication,
release of soluble factors and cell-to-cell contact, and are still
being actively investigated.
Electrical activity and proper axonal function are
required for developmental myelination (Demerens et al.,
1996; Wake et al., 2011). In fact, it is likely that synchronization between oligodendrocyte developmental programs and
specific patterns of axonal activity is crucial for timing of oligodendrocyte differentiation and initiation of myelination.
Furthermore, imaging studies have demonstrated that neuronal activity and learning cause structural changes in white
matter regions of the brain; although the underlying cellular
November 2014

and molecular events are still largely unknown (see Zatorre
et al., 2012 for review). Recent behavioral studies identified a
critical developmental period for social experience-dependent
oligodendrocyte maturation and myelination (Makinodan
et al., 2012), as well as impaired myelination in the adult
brain caused by social isolation (Liu et al., 2012). These studies strongly suggest that experience-dependent neuronal activity results in white matter plasticity both in the developing
and adult brain.
Earlier studies in the CNS demonstrated that blockage
of action potentials in axons results in defective myelination,
whereas increase in electrical activity enhances myelination
(Demerens et al., 1996). The mechanisms by which electrical
activity in axons influence myelination are still incompletely
defined, although axonal signals, e.g., glutamate and adenosine, that are released by specific patterns of electrical stimulation in axons and regulate myelination have been identified
(Stevens et al., 2002; Wake et al., 2011). Adenosine is
thought to act on purinergic receptors expressed by OPCs
(Stevens et al., 2002), whereas glutamate is believed to act on
receptors of the AMPA, kainate and NMDA subtype (Gallo
et al., 1996; Karadottir et al., 2005; Kukley et al., 2007; Patneau et al., 1994; Ziskin et al., 2007). Importantly, astrocytes
are also involved in activity-dependent regulation of myelination and cooperate with other neural cell types to modulate
this process. ATP released by axons through specific patterns
of stimulation induces release of cytokine leukemia inhibitory
factor (LIF) by astrocytes, which in turn promotes myelination (Ishibashi et al., 2006). More recently, electrical activity
was found to promote myelination in a frequency-dependent
fashion, and neuronal cAMP was identified as a major mediator of this effect (Malone et al., 2013). However, direct evidence that electrical activity per se modulates remyelination in
the CNS in vivo is still lacking.
Compromised axonal function is likely to further reduce
remyelination potential, as distribution of metabolites, organization of ionic channels and patterns of electrical activity are
permanently altered (see Franklin and ffrench-Constant, 2008,
for review). Therefore, it is important to understand how
demyelination impacts functional organization of axons and
ultimately their physiological properties. First, mitochondrial
functions are severely affected in degenerating axons (Dutta
et al., 2006), as axonal ATP is depleted and Na1-K1 ATPase
failure occurs as a consequence of inflammation (Smith, 2007).
This causes a reduced ability of axons to prevent pathological
Na1 influx and to extrude Na1 ions. Higher intracellular Na1
concentrations in axons trigger a cascade of events, including
enhanced Na1-Ca21 exchange channel activity, increased Ca21
influx, activation of proteases, and disruption of neurofilament
integrity and axonal transport (Dutta et al., 2006; Stys et al.,
1992). Consistent with this hypothesis, in MS tissue and
1909

animal models, the number of mitochondria in axons significantly changes as a result of demyelination and during remyelination, as demonstrated by immunolabeling with antibodies
against porin, a voltage-gated anion channel selectively
expressed in the mitochondrial membrane (Zambonin et al.,
2011). In particular, mitochondrial content significantly
increases in chronically or acutely demyelinated axons, and
decreases during remyelination, although the overall number of
mitochondria in remyelinated axons is still higher than in
myelinated axons (Zambonin et al., 2011). These results indicate that demyelinated axons display a large increase in energy
demand, which is partially attenuated by remyelination.
Myelin plays an essential role in organization of axonal
domains, because the organization of nodal, paranodal, and
juxtaparanodal proteins, including ion channels, is severely
compromised in demyelinated axons (see Waxman, 2006 for
a review). In demyelinated axons, voltage-gated Na1 channel
(NaV) expression and nodal distribution are significantly
altered—in particular the small conductance channel NaV 1.2
is upregulated and more evenly redistributed on the intermodal axolemma (Craner et al., 2003). Furthermore, the larger
conductance NaV 1.6 channels, which are normally segregated at the nodes of Ranvier after myelination, are also more
evenly distributed on axons (Craner et al., 2004). Similar
neuronal abnormalities were also detected in MS tissue (Craner et al., 2004). Therefore, it is likely that a large upregulation of Na1 conductance will cause a drastic increase in
intra-axonal Na1 ions, with subsequent protease activation
and axonal loss.
Expression and distribution of paranodal (paranodin/
Caspr) and juxtaparanodal (Kv channels and Caspr) proteins
is also altered in demyelinated axons found in MS tissue, as
they are all diffusely distributed, rather than clustered in specific domains (Coman et al., 2006). Conversely, in remyelinated lesions (shadow plaques and partially remyelinated
plaques), aggregates of nodal and perinodal constituents were
detected (Coman et al., 2006), further indicating that myelin
contributes to maintaining normal distribution of axonal proteins. Thus, demyelination causes major changes in fundamental structural and physiological properties of axons, which
prevent normal saltatory conduction and disrupt normal axoglial interactions. These abnormalities of intrinsic axonal
properties contribute to inhibition of myelin repair, which in turn
further compromises axonal viability leading to degeneration.
A different type of axonal-oligodendroglial communication has been recently characterized, based on the pioneering
work of Bergles and colleagues demonstrating the presence of
synapses on NG2-expressing OPCs (Bergles et al., 2000).
Although these neuron-NG2 cell synapses were originally
identified in gray matter, they are also found in NG2 cells
present in white matter, both under normal physiological
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conditions (Kukley et al., 2007; Ziskin et al., 2007) and after
demyelination (Etxeberria et al., 2010). Axon collaterals in
corpus callosum make direct synaptic contacts with OPCs,
which receive both glutamatergic and GABAergic synapses
(Lin and Bergles, 2003). At early postnatal developmental
stages both neurotransmitter amino acids depolarize the NG2
cell membrane. Recent evidence indicates that glutamate regulates NG2 cell proliferation and differentiation in vivo
(Mangin et al., 2012), as previously observed in OPCs in different culture systems (Gallo et al., 1996; Yuan et al., 1998).
The direct demonstration of synapses being present on
actively dividing NG2 cells (Ge et al., 2009; Kukley et al.,
2008) is consistent with a developmental function, in particular on cell proliferation. Furthermore, downregulation of
neuron-NG2 cell synapses occurs as OPCs mature to premyelinating and myelinating OLs (De Biase et al., 2010),
indicating a specific role for these synapses at earlier developmental stages that precede myelination (Gallo et al., 2008).
Synaptic communication between neurons and OPCs
is likely to regulate not only OPC development, but also
oligodendrocyte regeneration and remyelination. NG2 cells
in the SVZ do not display synaptic contacts with neurons;
however, they receive glutamatergic synaptic inputs from
axonal collaterals once they migrate from the SVZ into the
corpus callosum within a few days after toxin-induced focal
demyelination (Exteberria et al., 2010). Similar to the process that occurs during development, these synaptic inputs
are also downregulated at more mature stages during
remyelination (Exteberria et al., 2010). Therefore, axons
still establish and maintain contacts with NG2 cells during
early phases of remyelination, suggesting that glutamateinduced depolarization contributes to NG2 cell cycle exit
and initiation of differentiation also under pathological
conditions.
In addition to soluble factors and neurotransmitters,
membrane-bound molecules present in axons regulate myelination, and likely remyelination. The immunoglobulin superfamily member’s neural cell adhesion molecules (NCAMs)
have been implicated in cell-cell adhesion and migration, and
their expression is developmentally regulated, indicating specific roles during critical phases of CNS maturation (Coman
et al., 2005). PSA-NCAM expression in axons is drastically
downregulated during myelination and its loss from the axonal surface coincides with initiation of myelination (Charles
et al., 2000). This suggests that PSA-NCAM is an inhibitor
of myelination, and downregulation of this adhesion molecule
is a necessary step to convert axons to a myelination permissive state. Studies in postmortem MS tissue are consistent
with this hypothesis. In fact, PSA-NCAM is normally absent
from the adult brain, but is re-expressed on demyelinated
axons present in MS plaques, and not in shadow plaques,
Volume 62, No. 11
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strongly suggesting that it might be one of the endogenous
inhibitors of remyelination in MS (Charles et al., 2002).
Semaphorins are known as developmental signals for
both neurons and glia in the CNS (Armendariz et al., 2012;
Pasterkamp, 2012). Semaphorins have emerged as important
regulators of both OPC migration and differentiation following demyelination. Developmental studies first identified semaphorins 3A and 3F as repulsive and attractive guidance cues
for OPCs, respectively. It has subsequently been shown that
adult OPCs express class 3 semaphorin receptors, neuropilins
and plexins and that neuropilin expression by OPCs increases
after demyelination. Gain and loss of function experiments
have shown that semaphorin 3A impairs OPC recruitment to
the demyelinated area, while semaphorin 3F overexpression
accelerates not only OPC recruitment, but also remyelination
rate (Piaton et al., 2011). Semaphorin 3A, which is expressed
at high levels in active MS lesions (Syed et al., 2011), also
reversibly inhibits OPC differentiation in culture and prevents
remyelination when infused in demyelinated lesions of the
CNS (Syed et al., 2011), indicating that this protein might
contribute to maintaining OPCs in an undifferentiated state
and limit their maturation under pathological conditions.
Axonal Protection and Remyelination
Myelin integrity is vital to axonal function and survival, as
demonstrated in earlier studies in transgenic mice in which the
myelin-specific genes Cnp or Plp were selectively deleted (Griffiths et al., 1998; Lappe-Siefke et al., 2003). In these mouse
mutants, myelin sheaths displayed only minor structural abnormalities, but axons progressively degenerated. The absence of
PLP protein directly affected axoplasmic transport and further
analysis identified the myelin-associated NAD-dependent
deacetylase sirtuin 2 as a molecular mediator of this effect
(Werner et al., 2007). Studies in human pathological tissues
are also consistent with the notion that myelin maintains axonal stability, as demonstrated in Pelizaeus-Merzbacher disease
(PMD) and in MS. PMD is caused by PLP gene mutations
and causes axon loss (Garbern et al., 2002), indicating that the
phenotype observed in animal models reproduces the human
disease. In MS tissue, white matter regions in which at least
partial remyelination occurred display enhanced preservation of
axons (Kornek et al., 2000), consistent with findings in animal
models demonstrating that remyelination is protective to axons
(Irvine and Blakemore, 2008). The cellular and molecular
mechanisms causally involved in the effects of myelin on axonal survival are being elucidated, and IGF1, BDNF and
GDNF have been identified as candidates for oligodendrocytederived trophic factors that promote axonal growth and survival (Smith et al., 2013; Wilkins et al., 2003). An intriguing
recent study has revealed activity-dependent axonal release of
the neurotransmitter glutamate triggering oligodendroglial
November 2014

secretion of exosomes carrying cargoes of specific proteins and
RNA that are taken up by neurons and improve neuronal viability (Fr€
uhbeis et al., 2013).
Oligodendrocytes and myelin also play a critical role in
metabolic support of axons under normal physiological conditions (Nave, 2010). The role of oligodendrocytes in maintaining long-term axonal integrity has been recognized for a
number of years, but only recently have some of the fundamental molecular mechanisms been defined. In particular,
both glucose and lactate have been identified as main regulators of oligodendrocyte development and myelination (Rinholm et al., 2011). Furthermore, metabolic coupling between
axons and oligodendrocytes has been demonstrated, with oligodendrocytes providing aerobic glycolysis products to axons
under conditions that cause energy deprivation (Funfschilling
et al., 2012). Finally, a crucial role for the lactate transporter
MCT1, which is highly enriched in oligodendrocytes, has
been recently revealed, as disruption of MCT1 causes axon
damage and neuronal loss (Lee et al., 2012). A role for oligodendroglial MCT1 has also been suggested in the pathogenesis of ALS (Lee et al., 2012).
These recent studies have further elucidated how oligodendrocyte loss and demyelination could impact short- and
long-term axonal integrity, and ultimately neuronal survival.
Conversely, oligodendrocyte regeneration and prompt remyelination would prevent axons from undergoing a sequence of
physiological changes that leads to irreversible damage.
Remyelination not only restores normal axonal conduction
and physiological patterns of electrical activity, but also protects axons from further inflammatory-induced degeneration
(Black et al., 2006).

Conclusion and Perspectives
The studies discussed above demonstrate that neurons and
oligodendrocytes form a unique, mutually beneficial cellular
partnership that can be severely affected by the compromised
viability of either cell type. To elucidate the functional role of
neurons and their activity on remyelination, future efforts
should be focused on developing experimental approaches
that will allow simultaneous monitoring of electrical activity
in axons and their myelination status in vivo. These
approaches should be combined with integrated analysis in
animal models and in human brain. Field potential recordings
(Crawford et al., 2009) combined with imaging techniques
(Zatorre et al., 2012) will allow a more accurate evaluation of
action potential propagation along axons and functional
integrity of white matter regions.
Diffusion tensor imaging studies and the use of more
sophisticated multimodal imaging techniques will help define
real-time microstructural changes occurring in white matter
during remyelination. In neurons, these changes relate to
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axon number and diameter, axon density, axon branching and
directionality, and extent of remyelination. In non-neuronal
cells, changes in macroglia and microglia number and size, as
well as angiogenesis will affect imaging results. A relatively
new MR technique, serial magnetization transfer (MT), that
appears to be particularly sensitive to detecting myelination
(Laule et al., 2007), has been used to evaluate demyelination,
axonal loss and nerve degeneration (Horsfield, 2005). Furthermore, MT was also used to investigate natural variation of
white matter microstructure and composition in healthy subjects (Kang et al., 2011). This experimental approach is also
useful to better determine myelin content and distribution in
disease. Finally, positron emission tomography can be used to
image vital stains for myelin (Stankoff et al., 2011) and maps
of multi-exponential T2 relaxation times can provide myelin
measures (Laule et al., 2007).
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